Summary
The prognostic significance of the proliferative activities in intraductal components and invasive foci was investigated using 157 cases of invasive ductal breast carcinoma in which intraductal components predominated. Proliferative activity was expressed as the number of MIB1-positive nuclei per 1000 cancer cells in the most active areas of intraductal components (MLI-DCIS) or invasive foci (MLI-INV). MLI-DCIS correlated closely with MLI-INV (r = 0.710, 95% confidence interval, 0.623–0.780; P< 0.0001). Both MLI-DCIS and MLI-INV were related to oestrogen receptor (ER) (P = 0.0006, P = 0.0028 respectively), grade of invasive tumour (P< 0.0001, P< 0.0001 respectively) and classification of intraductal components (P< 0.0001, P< 0.0001 respectively). In the univariate disease-free survival analysis, both MLI-DCIS and MLI-INV were found to be significant (P< 0.0001, P = 0.0003 respectively). However, in node-negative cases, only MLI-DCIS was significant (P = 0.0416). Multivariate analysis revealed that MLI-DCIS was significant not only in all cases, but also in node-negative cases (P = 0.0223, P = 0.0426 respectively), whereas MLI-INV was not. These findings indicate that MIB1-determined proliferative activity of intraductal components is a significant prognostic determinant of invasive ductal breast carcinoma in which intraductal components predominate.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Barbareschi, M., Girlando, S., Mauri, F. M., Forti, S., Eccher, C., Mauri, F. A., Togni, R., Palma, P. D. & Doglioni, C. (1994). Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 102: 171–175.
Bartelink, H., Borger, J. H., van Dongen, J. A. & Peterse, J. L. (1988). The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol 11: 297–303.
Cattoretti, G., Becker, M. H. G., Key, G., Duchrow, M., Schlüter, C., Galle, J. & Gerdes, J. (1992). Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357–363.
Collan, Y. U. I., Kuopio, T., Baak, J. P. A., Becker, R., Bogomoletz, W. V., Deverell, M., van Diest, P., van Galen, C., Gilchrist, K., Javed, A., Kosma, V-M, Kujari, H., Luzi, P., Mariuzzi, G. M., Matze, E., Montironi, R., Scarpelli, M., Sierra, D., Sisti, S., Toikkanen, S., Tosi, P., Whimster, W. F. & Wisse, E. (1996). Standardized mitotic counts in breast cancer evaluation of the method. Pathol Res Pract 192: 931–941.
Dettmer, P., Harbeck, N., Thomssen, C., Pache, L., Ziffer, P., Fizi, K., Jänicke, F., Nathrath, W., Schmitt, M., Graeff, H. & Höfler, H. (1997). Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75: 1525–1533.
Elston, C. W. & Ellis, I. O. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410.
Gerdes, J., Schwab, U., Lemke, H. & Stein, H. (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13–20.
Gupta, S. K., Douglas-Jones, A. G., Fenn, N., Morgan, J. M. & Mansel, R. E. (1997). The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer 80: 1740–1745.
Haerslev, T., Jacobsen, G. K. & Zedeler, K. (1996). Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37: 101–113.
Hall, P. A. & Levison, D. A. (1990). Review: assessment of cell proliferation in histological material. J Clin Pathol 43: 184–192.
Holland, R., Peterse, J. L., Millis, R. R., Eusebi, V., Faverly, D., VandeVijver, M. J. & Zafrani, B. (1994). Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167–180.
Imamura, H., Haga, S., Shimizu, T., Watanabe, O., Kajiwara, T. & Aiba, M. (1997). MIB1-determined proliferative activity in intraductal components and prognosis of invasive ductal breast carcinoma. Jpn J Cancer Res 88: 1017–1023.
Kamel, O. W., Franklin, W. A., Ringus, J. C. & Meyer, J. S. (1989). Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol 134: 107–113.
Keshgegian, A. A. & Cnaan, A. (1995). Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104: 42–49.
Kurtz, J. M., Jacquemier, J., Amalric, R., Brandone, H., Ayme, Y., Hans, D., Bressac, C., Roth, J. & Spitalier, J-M (1990). Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer 65: 1867–1878.
Linden, M. D., Torres, F. X., Kubus, J. & Zarbo, R. J. (1992). Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol (Suppl.) 97: 4–13.
Lloveras, B., Edgerton, S. & Thor, A. D. (1991). Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit. Am J Clin Pathol 95: 41–47.
McGurrin, J. F., Doria, M. I., Dawson, P. J., Karrison, T., Stein, H. O. & Franklin, W. A. (1987). Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer 59: 1744–1750.
Meyer, J. S. (1986). Cell kinetics of histologic variants ofin situbreast carcinoma. Breast Cancer Res Treat 7: 171–180.
Meyer, J. S., Prey, M. U., Babcock, D. S. & McDivitt, R. W. (1986). Breast carcinoma cell kinetics, morphology, stage, and host characteristics. Lab Invest 54: 41–51.
Mourad, W. A., Setrakian, S., Hales, M. L., Abdulla, M. & Trucco, G. (1994). The argyrophilic nucleolar organizer regions in ductal carcinoma in situ of the breast. Cancer 74: 1739–1745.
Pietiläinen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V-M & Syrjänen, K. (1996). The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122: 687–692.
Pinder, S. E., Wencyk, P., Sibbering, D. M., Bell, J. A., Elston, C. W., Nicholson, R., Robertson, J. R., Blamey, R. W. & Ellis, I. O. (1995). Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71: 146–149.
Raymond, W. A. & Leong, AS-Y (1989). Nucleolar organizer regions relate to growth fractions in human breast carcinoma. Hum Pathol 20: 741–746.
Silvestrini, R., Daidone, M. G., Luisi, A., Mastore, M., Leutner, M. & Sarvadori, B. (1997). Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J Cancer 74: 122–127.
Weidner, N., Moore, D. H., Ljung, B-M, Waldman, F. M., Goodson, W. H., Mayall, B., Chew, K. & Smith, H. S. (1993). Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am J Surg Pathol 17: 987–994.
Weidner, N., Moore, D. H. & Vartanian, R. (1994). Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel ‘paraffin’-reactive MIB1 antibody. Hum Pathol 25: 337–342.
Woosley, J. T. (1991). Measuring cell proliferation. Arch Pathol Lab Med 115: 555–557.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Imamura, H., Haga, S., Shimizu, T. et al. Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma. Br J Cancer 79, 172–178 (1999). https://doi.org/10.1038/sj.bjc.6690029
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690029
Keywords
This article is cited by
-
Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia
Breast Cancer Research and Treatment (2010)